Need for Drug Resistance Screening in H.pylori

A recently published study about the use of the Hain Lifescience Genotype HelicoDR has highlighted its importance for the detection of resistance mutations in Helicobacter pylori. H.pylori is a bacterium that affects patients protective barriers against stomach acids. Prolonged, untreated infections can lead to stomach ulceration and in some cases (approximately 1% of infections) to gastric cancer.

Drug resistance associated with H.pylori is becoming an increasing problem worldwide. Global resistance to clarithromycin is estimated between 40-50% of cases (this can increase to as much as 80% in patients who have previously been treated).

The study by Cambau et al details the need for better surveillance of drug resistance by the use of a molecular assay. The paper concluded 'GenoType HelicoDR is efficient at detecting mutations predictive of antibiotic resistance in H. pylori when applied to strains or directly to gastric biopsy specimens.'

The Hain Lifescience Genotype HelicoDR is a simple to use, rapid molecular assay that simultaneously detects H.pylori and key resistance markers for clarithromycin and fluoroquinolones. The test offers a cost effective solution to ensuring that patients are provided with appropriate and effective therapy.

For full details on the study 'Evaluation of a New Test, GenoType HelicoDR, for Molecular Detection of Antibiotic Resistance in Helicobacter pylori' by Cambau et al, please click here

For details on the Hain Lifescience HelicoDR, please click here